EBV EBNA3A (158-166) (HLA-B8)
Ref. 3D-CRB1001459
| 1mg | 184.00 € | ||
| 500µg | 149.00 € |
Product Information
- QAKWRLQTL-acidH-Gln-Ala-Lys-Trp-Arg-Leu-Gln-Thr-Leu-OH
EBV EBNA3A (158-166) (HLA-B8) is an immunodominant CEF control peptide that is derived from the Epstein-Barr virus (EBV). EBV targets B cells, which can cause lytic infection and the consequent death of these cells. Natural killer (NK) cells, invariant (iNKT) cells, CD4T cells and CD8 T cells are essential to control the action of EBV-infected cells. EBV EBNA3A (158-166) (HLA-B8) is defined as a CEF control peptide due to its antigenic properties. Clinically, this peptide is a suitable epitope for CD8+ T cells and can be used to stimulate the release of IFNg. HLA-B8 refers to the cell HLA type that this peptide acts on.The Epstein-Barr nuclear antigen 3A (EBNA3A) protein plays a significant role in reprogramming the gene expression of host cells. The action of this protein affects cell proliferation, survival, differentiation and immune surveillance. EBNA3A also targets tumour suppressor pathways in the infected B cells, meaning it is considered an oncoprotein.
Chemical properties
Technical inquiry about: 3D-CRB1001459 EBV EBNA3A (158-166) (HLA-B8)
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
